Hair Loss Treatment Advances From Abroad
Yuyu Pharma shared its plans to conduct clinical trials in the U.S. and Europe for its Dutasteride Tablet ("DUT") for the treatment of Androgenetic Alopecia ("AGA") at the World Congress for Hair Research 2022 in Melbourne, Australia.
DUT was created to improve the patient experience by creating a tablet smaller in size, while keeping the exact same dosage of 0.5 mg. There are plans to have a pre-IND meeting with the U.S. FDA and Scientific Advice meeting with Europe's EMA in 2023.
Related: Brexogen's 'BRE-AD01' Accepted for Phase 1 Clinical Trials by US FDA
"Dutasteride has been approved and is prescribed to patients with AGA in Korea and Japan. But it is not approved as a hair loss treatment in the U.S. and Europe. We hope to do trials to get AGA on-label in both US and Europe," said Wonsang Robert Yu, CEO of Yuyu Pharma.
Dutasteride inhibits both Type I and Type II five-alpha reductase, which acts to transform testosterone into a DHT hormone. In scientific studies, excess DHT is understood to be the root cause of hair loss.
